
Over the last 7 days, the Clinical Research and Equipment industry has risen 3.3%, driven by gains from Locus Cell of 17%. During this same period, the EirGenix underperformed, falling 5.6%. The industry has been flat over the past 12 months despite the gain this week.
Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 27 May 2026 | NT$33.3b | NT$2.7b | -NT$746,869,000.00 | 20.8x | -44.6x | 12.6x |
| Fri, 24 Apr 2026 | NT$35.7b | NT$2.5b | -NT$767,980,000.00 | 22.1x | -46.5x | 14.3x |
| Sun, 22 Mar 2026 | NT$31.4b | NT$2.5b | -NT$747,966,000.00 | 20.6x | -41.9x | 12.5x |
| Tue, 17 Feb 2026 | NT$33.3b | NT$2.4b | -NT$689,929,000.00 | 23.8x | -48.3x | 13.7x |
| Thu, 15 Jan 2026 | NT$34.9b | NT$2.4b | -NT$689,929,000.00 | 25.2x | -50.6x | 14.4x |
| Sat, 13 Dec 2025 | NT$35.6b | NT$2.4b | -NT$670,921,000.00 | 21.3x | -53x | 14.5x |
| Mon, 10 Nov 2025 | NT$35.3b | NT$2.5b | -NT$870,437,000.00 | 17.4x | -40.6x | 14.4x |
| Wed, 08 Oct 2025 | NT$38.6b | NT$2.5b | -NT$870,437,000.00 | 19.3x | -44.3x | 15.7x |
| Fri, 05 Sep 2025 | NT$35.3b | NT$2.5b | -NT$819,216,000.00 | 20.5x | -43.1x | 14.4x |
| Sun, 03 Aug 2025 | NT$33.4b | NT$2.5b | -NT$600,003,000.00 | 21.5x | -55.7x | 13.6x |
| Tue, 01 Jul 2025 | NT$33.0b | NT$2.5b | -NT$600,003,000.00 | 22.9x | -55x | 13.4x |
| Thu, 29 May 2025 | NT$34.0b | NT$2.5b | -NT$600,003,000.00 | 22.2x | -56.7x | 13.8x |
| Sat, 26 Apr 2025 | NT$31.1b | NT$2.5b | -NT$540,128,000.00 | 23.7x | -57.6x | 12.6x |
| Mon, 24 Mar 2025 | NT$36.6b | NT$2.4b | -NT$560,979,000.00 | 28.5x | -65.2x | 15.2x |
| Wed, 19 Feb 2025 | NT$37.3b | NT$2.6b | -NT$854,432,000.00 | 23.6x | -43.6x | 14.5x |
| Fri, 17 Jan 2025 | NT$36.8b | NT$2.6b | -NT$854,432,000.00 | 23.2x | -43x | 14.3x |
| Sun, 15 Dec 2024 | NT$33.7b | NT$2.6b | -NT$854,432,000.00 | 24.8x | -39.4x | 13.1x |
| Tue, 12 Nov 2024 | NT$41.7b | NT$2.5b | -NT$712,402,000.00 | 24.1x | -58.6x | 16.6x |
| Thu, 10 Oct 2024 | NT$41.6b | NT$2.3b | -NT$836,610,000.00 | 21.8x | -49.7x | 18.3x |
| Sat, 07 Sep 2024 | NT$40.3b | NT$2.3b | -NT$836,610,000.00 | 22.5x | -48.1x | 17.7x |
| Mon, 05 Aug 2024 | NT$41.5b | NT$2.1b | -NT$797,765,000.00 | 32x | -52x | 19.4x |
| Wed, 03 Jul 2024 | NT$45.9b | NT$2.1b | -NT$797,765,000.00 | 35.3x | -57.6x | 21.5x |
| Fri, 31 May 2024 | NT$40.2b | NT$2.1b | -NT$797,765,000.00 | 32.3x | -50.4x | 18.8x |
| Sun, 28 Apr 2024 | NT$39.4b | NT$2.1b | -NT$914,899,000.00 | 31.6x | -43.1x | 18.6x |
| Tue, 26 Mar 2024 | NT$40.6b | NT$2.1b | -NT$606,177,000.00 | 31.4x | -66.9x | 19.6x |
| Thu, 22 Feb 2024 | NT$44.1b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -72.2x | 21.2x |
| Sat, 20 Jan 2024 | NT$44.2b | NT$2.1b | -NT$610,218,000.00 | 32.9x | -72.5x | 21.3x |
| Mon, 18 Dec 2023 | NT$48.6b | NT$2.1b | -NT$610,218,000.00 | 32.8x | -79.7x | 23.4x |
| Wed, 15 Nov 2023 | NT$47.9b | NT$2.2b | -NT$503,183,000.00 | 31.6x | -95.1x | 21.5x |
| Fri, 13 Oct 2023 | NT$48.1b | NT$2.2b | -NT$497,769,000.00 | 31.1x | -96.7x | 21.6x |
| Sun, 10 Sep 2023 | NT$43.1b | NT$2.2b | -NT$497,769,000.00 | 31.3x | -86.5x | 19.4x |
| Tue, 08 Aug 2023 | NT$46.8b | NT$2.4b | -NT$281,587,000.00 | 44.4x | -166.1x | 19.1x |
| Thu, 06 Jul 2023 | NT$48.9b | NT$2.5b | -NT$274,767,000.00 | 43.1x | -178x | 19.9x |
| Sat, 03 Jun 2023 | NT$50.0b | NT$2.5b | -NT$274,899,000.00 | 43.7x | -181.8x | 20.2x |
-181.8x
How does Taiwanese Clinical Research and Equipment compare with similar industries?
| TW Market | 6.63% | |
| Healthcare | 1.85% | |
| Life Sciences | 3.29% | |
| Clinical Research and Equipment | 3.29% | |
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6891 Locus Cell | NT$58.20 | 17.2% +NT$1.7b | 164.5% | PS914x | |
| 6848 RBC Bioscience | NT$19.60 | 1.8% +NT$4.5m | 18.5% | PE10.8x | |
| 6661 Welgene BiotechLtd | NT$17.60 | 0.9% +NT$3.5m | -18.9% | PS1.1x |